Ophthalmology-focused medical device supplier VisionX has secured over $100 million for its Series B round of financing, per a company statement on Thursday. The round attracted two new investors – Temasek Holdings and Lake Bleu Capital. Return backers Sequoia Capital China, Green Pine Capital Partners and investment firms – Sherpa Healthcare Partners, 3H Health, Highlight Capital – joined the round. VisionX expects to deploy the capital for talent recruitment, R&D and commercialisation of new candidates. VisionX’s therapy areas target prevention of myopia in teenagers, eyesight correction for adults, ocular surface diseases, optometry diagnostics therapy and equipment, vision nursing and eyesight…